Compare · GILD vs LONA
GILD vs LONA
Side-by-side comparison of Gilead Sciences Inc. (GILD) and LeonaBio Inc. (LONA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and LONA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.03B, about 1995.7x LONA ($77.7M).
- Over the past year, GILD is up 17.6% and LONA is up 178.6% - LONA leads by 161.0 points.
- GILD has been more active in the news (16 items in the past 4 weeks vs 1 for LONA).
- GILD has more recent analyst coverage (25 ratings vs 3 for LONA).
- Company
- Gilead Sciences Inc.
- LeonaBio Inc.
- Price
- $124.83+0.97%
- $8.25+3.51%
- Market cap
- $155.03B
- $77.7M
- 1M return
- -4.46%
- -12.51%
- 1Y return
- +17.58%
- +178.62%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2020
- News (4w)
- 16
- 1
- Recent ratings
- 25
- 3
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
- National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
Latest LONA
- LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
- Piper Sandler initiated coverage on LeonaBio with a new price target
- LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
- SEC Form DEFA14A filed by LeonaBio Inc.
- SEC Form DEF 14A filed by LeonaBio Inc.
- SEC Form 4 filed by Director Holles Natalie C.
- SEC Form 4 filed by Director Silverman Peter B.
- SEC Form 4 filed by Director Callori Fred
- SEC Form 3 filed by new insider Silverman Peter B.
- SEC Form 3 filed by new insider Holles Natalie C.